Evaluation and improvement of venous thromboembolism prophylaxis pattern in patients admitted to orthopedic ward in a tertiary teaching hospital Improvement of VTE prophylaxis
International Pharmacy Acta,
Vol. 5 No. 1 (2022),
19 Khordad 2022
,
Page e13: 1-6
https://doi.org/10.22037/ipa.v5i1.38782
Abstract
Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE incidence in major orthopedic surgery ranges from 40% to 60%. Several risk factors are responsible for VTE incidences, such as age, obesity and immobility. This study was designed and performed to evaluate the process of thromboprophylaxis in patients undergoing orthopedic surgery with and without pharmacist intervention to improve prescribing. A total of 306 patients were randomly enrolled in the two phases of this study. To investigate the cause of VTE, 201 patients receiving no pharmacist interference as study phase one and 105 patients receiving pharmacist interference as study phase two were evaluated. Rate of occurrence of risk was calculated using the Caprine scoring system. The trend of prescription and the reasons for not prescribing the drugs under consideration for the patients, were investigated. As a subsidiary aim to the study and to increase economical productivity, the prescription of heparin instead of other anticoagulating drugs was suggested in pharmacotherapy consultation. In the first phase of the research, it was proven that 161 (80.1%) of the patients under consideration needed the prophylaxis but 40 (19.9%) of them did not. After the investigation, 171 (85.1%) of the patients according to the guideline and 30 (14.9%) without considering the guideline underwent prophylaxis. In the second phase of the research, 40 (38.1%) of the patients did not require prophylaxis treatment but 65 (61.9%) did. After investigation and drug interaction results, 96 (91.43%) according to the guideline and 9 without considering the guideline were treated with the prophylaxis drug. Despite the active presence and cooperation of pharmacists, 4.76% who did not need prophylaxis received it, and 6.15% who needed prophylaxis did not receive it despite the pharmacist's intervention. Moreover, 2.86% of patients who were prohibited from taking enoxaparin were allowed to take heparin after pharmacist intervention. This research showed that active cooperation between orthopedist and pharmacist in prescribing the required drug(s) is very low. For this reason, the continuous presence of a pharmaceutical group as well as changes in protocols can serve as an effective, logical step in the prescription of drugs.
- prophylaxis
- venous thromboembolism
- orthopedic
- heparin
- enoxaparin
How to Cite
References
Vincent, J.-L., et al., Textbook of Critical Care E-Book. 2011: Elsevier Health Sciences.
Previtali, E., et al., Risk factors for venous and arterial thrombosis. Blood Transfus, 2011. 9(2): p. 120-38.
Aslan, A., et al., Drug updates for prevention and treatment of venous thromboembolism in orthopedic surgeries. Iranian Journal of Cardiovascular Nursing, 2017. 6(2): p. 66-73.
Bauer, K.A. and G.Y. Lip, Overview of the causes of venous thrombosis. UpToDate. Waltham, 2017.
Segon, Y.S., et al., Surgical venous thromboembolism prophylaxis: clinical practice update. Hospital Practice, 2020. 48(5): p. 248-257.
Zambelli, R., et al., High risk of venous thromboembolism after orthopedic surgery in patients with thrombophilia. Journal of Thrombosis and Haemostasis, 2021. 19(2): p. 444-451.
Sharif-Kashani, B., et al., Sticker reminders improve thromboprophylaxis appropriateness in hospitalized patients. Thrombosis research, 2010. 126(3): p. 211-216.
Shohani, M., et al., Prophylaxis against deep venous thrombosis in patients hospitalized in surgical wards in one of the Hospitals in Iran: Based on the american college of chest physician's protocol. International journal of preventive medicine, 2018. 9.
Mokhtari, M., A Multinational Middle Eastern Survey Of Venous Thromboembolism (VTE) Risk And Prophylaxis, in A106. ADVANCES IN DIAGNOSIS AND TREATMENT OF PULMONARY EMBOLISM. 2012, American Thoracic Society. p. A2361-A2361.
Levine, M., et al., Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. The Lancet, 1994. 343(8902): p. 886-889.
Krauss, E.S., et al., Implementation and validation of the 2013 Caprini score for risk stratification of arthroplasty patients in the prevention of venous thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2019. 25: p. 1076029619838066.
Farfan, M., et al., Worldwide adherence to ACCP guidelines for thromboprophylaxis after major orthopedic surgery: A systematic review of the literature and meta-analysis. Thrombosis research, 2016. 141: p. 163-170.
Lobastov, K.V., et al., [Caprini score as individual risk assessment model of postoperative venous thromboembolism in patients with high surgical risk]. Khirurgiia (Mosk), 2014(12): p. 16-23.
du Prel, J.B., et al., Choosing statistical tests: part 12 of a series on evaluation of scientific publications. Dtsch Arztebl Int, 2010. 107(19): p. 343-8.
ESMAILIJAH, A.A., et al., Comparing the Efficacy of Clexane and Enoxan in thromboprophylaxis after Total hip and knee arthroplasty. journal of medical council of islamic republic of iran, 2016. 34(2): p. 0-0.
Oster, G., et al., Economic consequences of venous thromboembolism following major orthopedic surgery. Annals of Pharmacotherapy, 2004. 38(3): p. 377-382.
Chari, A., et al., Venous thromboembolism and its prophylaxis in elective total hip arthroplasty: an international perspective. Hip International, 2012. 22(1): p. 1-8.
Sharrock, N.E., et al., Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clinical orthopaedics and related research, 2008. 466(3): p. 714-721.
Shoda, N., et al., Prophylactic effect of fondaparinux and enoxaparin for preventing pulmonary embolism after total hip or knee arthroplasty: A retrospective observational study using the Japanese Diagnosis Procedure Combination database. Modern rheumatology, 2015. 25(4): p. 625-629.
Mirdamadi, A., et al., Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial. ARYA atherosclerosis, 2014. 10(6): p. 292.
Zou, Y., et al., Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. Blood Coagulation & Fibrinolysis, 2014. 25(7): p. 660-664.
Rachidi, S., et al., The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert review of hematology, 2013. 6(6): p. 677-695.
Mokhtari, M., et al., The AVAIL ME Extension: a multinational Middle Eastern survey of venous thromboembolism risk and prophylaxis. Journal of Thrombosis and Haemostasis, 2011. 9(7): p. 1340-1349.
Amirsadri, M., S. Mousavi, and A. Karimipour, The cost-effectiveness and cost-utility analysis of the use of enoxaparin compared with heparin for venous thromboembolism prophylaxis in medical inpatients in Iran. DARU Journal of Pharmaceutical Sciences, 2019. 27(2): p. 627-634.
- Abstract Viewed: 124 times
- IPA-2022-Vol5-e13-38782 Downloaded: 159 times